CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 164 filers reported holding CLOVIS ONCOLOGY INC in Q4 2015. The put-call ratio across all filers is 0.74 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $91,000 | -69.4% | 18,924 | -62.9% | 0.00% | -100.0% |
| Q3 2020 | $297,000 | +133.9% | 51,011 | +171.8% | 0.00% | – |
| Q2 2020 | $127,000 | +15.5% | 18,770 | +8.8% | 0.00% | – |
| Q1 2020 | $110,000 | +129.2% | 17,249 | +433.2% | 0.00% | – |
| Q2 2019 | $48,000 | -82.0% | 3,235 | -36.1% | 0.00% | -100.0% |
| Q1 2018 | $267,000 | -22.6% | 5,060 | -0.3% | 0.00% | -50.0% |
| Q4 2017 | $345,000 | -20.5% | 5,073 | -3.6% | 0.00% | 0.0% |
| Q3 2017 | $434,000 | -9.0% | 5,261 | +3.3% | 0.00% | -33.3% |
| Q2 2017 | $477,000 | +49.5% | 5,093 | +1.7% | 0.00% | +50.0% |
| Q1 2017 | $319,000 | +10.8% | 5,010 | +60.2% | 0.00% | -33.3% |
| Q3 2015 | $288,000 | +14.7% | 3,127 | +9.7% | 0.00% | 0.0% |
| Q2 2015 | $251,000 | +16.2% | 2,851 | -2.1% | 0.00% | +50.0% |
| Q1 2015 | $216,000 | – | 2,912 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 407,416 | $14,259,560,000 | 8.34% |
| Palo Alto Investors LP | 3,547,719 | $124,170,000 | 6.91% |
| Antipodean Advisors LLC | 1,268,658 | $44,403,000 | 6.48% |
| Redmile Group, LLC | 1,795,936 | $62,858,000 | 4.70% |
| HealthCor Management, L.P. | 1,525,000 | $53,375,000 | 3.24% |
| PointState Capital LP | 3,503,900 | $122,637,000 | 3.12% |
| NEA Management Company, LLC | 1,139,890 | $39,896,000 | 2.54% |
| CLIFTON PARK CAPITAL MANAGEMENT, LLC | 612,500 | $21,438,000 | 2.44% |
| PFM Health Sciences, LP | 2,078,440 | $72,745,000 | 2.21% |
| Partner Investment Management, L.P. | 35,300 | $1,236,000 | 2.03% |